Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neutrophil-derived vesicles control complement activation to facilitate inflammation resolution.

Cell·2025
Same author

FHL2 deficiency aggravates Candida albicans infection through decreased myelopoiesis.

Science China. Life sciences·2025
Same author

New insights into constitutive neutrophil death.

Cell death discovery·2025
Same author

DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways.

Frontiers in immunology·2024
Same author

The effect of transient, constricted migration on neutrophil intracellular bacteria-killing capability.

Immunity·2024
Same author

LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma.

Haematologica·2024

Related Experiment Video

Updated: Jan 18, 2026

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.5K

Improving predictive accuracy in multiple myeloma using a plasma cell profile derived from single-cell RNA

Lanting Liu1, Hao Sun1, Fangshuo Feng1

  • 1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600.

Haematologica
|May 29, 2025
PubMed
Summary

Researchers identified a seven-gene signature in aggressive multiple myeloma (MM) cells. This signature improves risk stratification for ultra-high-risk MM patients, aiding personalized treatment strategies.

More Related Videos

A Combinatorial Single-cell Approach to Characterize the Molecular and Immunophenotypic Heterogeneity of Human Stem and Progenitor Populations
09:34

A Combinatorial Single-cell Approach to Characterize the Molecular and Immunophenotypic Heterogeneity of Human Stem and Progenitor Populations

Published on: October 25, 2018

7.1K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.7K

Related Experiment Videos

Last Updated: Jan 18, 2026

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.5K
A Combinatorial Single-cell Approach to Characterize the Molecular and Immunophenotypic Heterogeneity of Human Stem and Progenitor Populations
09:34

A Combinatorial Single-cell Approach to Characterize the Molecular and Immunophenotypic Heterogeneity of Human Stem and Progenitor Populations

Published on: October 25, 2018

7.1K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.7K

Area of Science:

  • Hematology
  • Genomics
  • Oncology

Background:

  • Multiple myeloma (MM) exhibits significant heterogeneity, complicating accurate risk stratification and personalized treatment.
  • Current clinical genetic testing struggles to fully capture the molecular complexity of MM, necessitating improved biomarkers.
  • Identifying novel biomarkers is crucial for enhancing risk assessment and tailoring therapies for MM patients.

Purpose of the Study:

  • To analyze intratumor heterogeneity in newly diagnosed multiple myeloma (MM) at single-cell resolution.
  • To identify aggressive myeloma cell subsets and associated molecular markers for improved risk stratification.
  • To develop and validate an integrated risk model for ultra-high-risk MM patients.

Main Methods:

  • Single-cell RNA sequencing of myeloma cells from 12 newly diagnosed MM patients.
  • Identification and characterization of aggressive tumor cell subclusters.
  • Development of a seven-gene signature and an integrated risk stratification model.
  • Validation of the model in five independent MM patient datasets.
  • Quantification of the gene signature using digital polymerase chain reaction (dPCR).

Main Results:

  • A highly aggressive myeloma cell subset was identified, characterized by chromosomal instability, drug resistance, and high-risk genes.
  • A seven-gene signature (LILRB4, CD74, TUBA1B, CCND2, HIST1H4C, ITGB7, CRIP1) showed significantly high expression in aggressive cells.
  • The seven-gene signature score independently predicted poor patient outcomes.
  • An integrated risk model incorporating the gene signature significantly improved risk discrimination, especially for ultra-high-risk patients.
  • The dPCR method for quantifying the gene signature demonstrated clinical utility in differentiating patient survival.

Conclusions:

  • The identified seven-gene signature effectively characterizes aggressive multiple myeloma.
  • An integrated risk stratification model combining the gene signature enhances prognostic accuracy for MM patients.
  • This approach, particularly the dPCR quantification, offers a valuable tool for clinical application and guiding risk-adapted treatment strategies for ultra-high-risk MM.